Computer-designed vaccine elicits potent antibodies against RSV
A first-of-its-kind nanoparticle vaccine candidate for respiratory syncytial virus (RSV) has been designed in an international research effort. RSV is second only to malaria as a cause of infant mortality worldwide. The new vaccine elicits potent neutralizing antibodies against RSV in both mice and monkeys. The animal research findings, reported March 7 in the journal Cell, pave the way for human clinical trials.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: Clinical Trials | Computers | Malaria | Malaria Vaccine | Nanotechnology | Pharmaceuticals | Respiratory Medicine | Vaccines | Veterinary Vaccinations